NeoPhore Limited

NeoPhore Limited is a small molecule neoantigen immuno-oncology company developing a pipeline of drugs targeting proteins in the DNA mismatch repair pathway. Its first-in-class MMR inhibitors aim to increase immunogenicity in solid tumors, making them more responsive to immunotherapy. This approach seeks to improve clinical outcomes for cancer patients.

Funding Round: Series B

Funding Amount: $39.5M

Date: 01-Feb-2024

Investors: CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, NEVA SGR, LIFTT, Simon Fiduciaria

Markets: Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, and Translational Medicine

HQ: Cambridge, Cambridgeshire, United Kingdom

Founded: 2017

Website: https://www.neophore.com/

LinkedIn: https://www.linkedin.com/company/neophore-ltd

Twitter: https://twitter.com/neophoreltd

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/neophore

Pitchbook: https://pitchbook.com/profiles/company/222255-64